The burden of severe hypertensive disorders of pregnancy on perinatal outcomes: a nationwide case-control study in Suriname

Zita D. Prüst, MD; Lachmi R. Kodan, MD, PhD, MSc; Thomas van den Akker, MD, PhD; Kitty W.M. Bloemenkamp, MD, PhD; Marcus J. Rijken, MD, PhD; Kim J.C. Verschueren, MD, PhD

BACKGROUND: Latin America and the Caribbean is the region with the highest prevalence of hypertensive disorders of pregnancy worldwide. In Suriname, where the stillbirth rate is the second highest in the region, it is not yet known which maternal factors contribute most substantially.

OBJECTIVE: The aims of this study in Suriname were to (1) study the impact of different types of maternal morbidity on adverse perinatal outcomes and (2) study perinatal birth outcomes among women with severe hypertensive disorders of pregnancy.

STUDY DESIGN: A case-control study was conducted between March 2017 and February 2018 during which time all hospital births (86% of total) in Suriname were included. We identified babies with adverse perinatal outcomes (perinatal death or neonatal near miss) and women with severe maternal morbidity (according to the World Health Organization Near Miss tool). Stillbirths and early neonatal deaths (<7 days) were considered perinatal death. We defined a neonatal near miss as a birthweight below 1750 g, gestational age <33 weeks, 5-minute Apgar score <7, and preterm intrauterine growth restriction <p3. Descriptive statistics and multivariate binary logistic regression analyses were conducted.

RESULTS: In the 1-year study period, adverse perinatal outcomes were reported for 638 singleton births of which 120 (18.8%) involved women with severe maternal morbidity. In most of these cases, the mother suffered severe hypertensive disorders of pregnancy (n=95/120, 79.2%). Severe hypertensive disorders of pregnancy were strongly associated with adverse perinatal outcomes (adjusted odds ratio, 11.1; 95% confidence interval, 8.3—14.9). The prevalence of severe hypertensive disorders of pregnancy in Suriname was 2.5% (234/9197). Of the 215 singleton pregnancies complicated by severe hypertensive disorders, adverse perinatal outcomes were reported for 44.2% of them (n=95/215; adjusted odds ratio, 11.1; 95% confidence interval, 8.3—14.9); perinatal death accounted for 18.1% of these cases (n=39/215; adjusted odds ratio, 8.6; 95% confidence interval, 5.8—12.7) and neonatal near miss accounted for another 26.0% (n=56/215). Women with severe hypertensive disorders of pregnancy had a preterm birth (<37 weeks) in 67.1% of the cases (n=143/215; adjusted odds ratio, 14.1; 95% confidence interval, 10.5—19.0), a baby with a low birthweight (<2500 g) in 62.2% of the cases (n=130/215; adjusted odds ratio, 10.8; 95% confidence interval, 8.1—14.5), and a baby with a low 5-minute Apgar score in 20.5% of the cases (n=43/215; adjusted odds ratio, 6.9; 95% confidence interval, 4.8—10.0).

CONCLUSION: In Suriname, severe hypertensive disorders of pregnancy are strongly associated with adverse perinatal outcomes, with an increased risk for preterm birth, low birthweight, low Apgar score, and perinatal mortality. Prevention, early diagnosis, and management of hypertensive disorders of pregnancy are expected to reduce perinatal deaths substantially. Recommendations to reduce perinatal deaths in Suriname include the establishment of a national health plan for the management of severe hypertensive disorders of pregnancy and the introduction of perinatal death and neonatal near miss reviews.

Key words: adverse perinatal outcome, Caribbean, eclampsia, hypertensive disorders of pregnancy, Latin America, perinatal mortality, pre-eclampsia, South America, Suriname

Introduction

Globally, >5 million babies die before or shortly after birth and many more newborns sustain severe morbidity.1,2 Perinatal mortality and severe morbidity are tragic birth outcomes that are often the consequence of maternal morbidity.3 Although it is known that the complications that cause severe maternal morbidity also contribute to adverse perinatal outcomes, the exact impact of different types of maternal morbidity...
Severe hypertensive disorders of pregnancy increased the risk for adverse perinatal outcomes by >10 times. Compared with other severe maternal morbidities, severe hypertensive disorders of pregnancy were by far the most frequent contributor to adverse perinatal outcomes in Suriname. In this setting, severe hypertensive disorders of pregnancy increased the risk for preterm birth, low birthweight, low Apgar score, and perinatal mortality to a larger extent than reported previously in low- or middle-income countries.

**What does this add to what is known?**

Hypertensive disorders of pregnancy have a substantial impact on perinatal outcomes. Early detection, prevention, and management of hypertensive disorders of pregnancy are essential for the reduction of perinatal deaths.

HDPs are known to significantly increase the risk for adverse perinatal outcomes, such as prematurity, intrauterine growth restriction, and perinatal mortality.1–7 HDPs are associated with maternal obesity, chronic hypertension, and diabetes, all of which have been increasing in recent decades, particularly in Latin America and the Caribbean.8–10 Latin America and the Caribbean are regions with the highest prevalence of HDPs worldwide and HDPs are therefore expected to have a considerable negative impact on the perinatal outcomes in this region.8,11 Despite the magnitude of the problem, HDPs in Latin America and the Caribbean is an understudied topic, and the burden on perinatal health is poorly understood.12

Suriname, a middle-income country in South America, is known to have the second highest stillbirth rate (14 per 1000 births) in the region.13,14 However, it is not yet known which factors contribute most significantly to the adverse perinatal outcomes (perinatal mortality, preterm birth, low birthweight, low Apgar score) and how perinatal deaths can be reduced further. We hypothesized that severe HDP is the maternal morbidity that has the largest negative impact on perinatal birth outcomes in Suriname. The objectives of this study were to assess the impact of different maternal morbidities on adverse perinatal outcomes and to study perinatal birth outcomes specifically among women with severe HDPs.

**Materials and Methods**

**Study design**

We conducted a nationwide case-control study in Suriname for 1 year from March 2017 to February 2018. We collected data from all the singleton babies with adverse perinatal outcomes and all the women with severe morbidities according to the World Health Organization (WHO) Near Miss tool. In addition, we collected data on all hospital births in Suriname (gestational age ≥22 weeks or birthweight ≥500 g). Women with and without adverse perinatal outcomes and with and without severe maternal morbidity (including severe HDPs) were studied.

**Setting**

Suriname is a multiethnic, middle-income country located on the northeast coast of South America with a population of approximately 560,000.15 Annually, there are about 10,000 live births in Suriname of which 86% occur in the country’s 5 hospitals, 10% occur in primary care, 4% at home, and 4% at unknown locations.16 Generally, all women with complications during pregnancy or birth are referred to the hospitals. In 2016, national, context-tailored obstetrical guidelines were developed and implemented among which was a guideline for HDPs.17 A more comprehensive description of the healthcare situation can be found in previous publications.14,18

**Variable definitions and outcomes**

Adverse perinatal outcome. In this study, an adverse perinatal outcome is defined as a perinatal death or a neonatal near miss. Perinatal death is the sum of stillbirths and early neonatal deaths.19 A stillbirth is defined as a baby born with no signs of life (gestational age of ≥22 weeks or a birthweight ≥500 g) and an early neonatal death is defined as a baby who is born alive but then dies within the first 7 days of life.19 In the existing literature, multiple definitions for neonatal near miss exist. We use the following definition20:

- a birthweight <1750 g and/or;
- a gestational age <33 weeks and/or;
- an Apgar score lower than 7 after 5 minutes and/or;
- a gestational age between 33 and 37 weeks with a birthweight under the third percentile.21 For this study, we added the last criterion to the existing neonatal near miss definition, because it was deemed clinically relevant in the assessment of neonatal near miss in Suriname.

Severe maternal morbidity. Different types of severe maternal morbidity were identified using the WHO maternal near miss tool.22 In concordance with this guideline, we prospectively identified all pregnant women with a potentially life-threatening complication (PLTC). PLTCs are “an extensive category of clinical conditions, including diseases that can threaten a woman’s life during pregnancy and labor and after termination of pregnancy” (disease or intervention criteria).22 A PLTC
becomes a life-threatening complication (LTC) (ie, a maternal near miss [MNM]), if there are signs of organ dysfunction22 (Supplemental Table 1 provides all definitions of [P]LTC).

Severe HDP is a (P)LTC and was used as an umbrella term for severe preeclampsia and eclampsia (a more elaborate description can be found in Supplemental Table 1). Severe preeclampsia was defined as a repeated blood pressure above 160/110 mm Hg with clinical or laboratory signs of severe preeclampsia.23 Eclampsia was defined as seizures during pregnancy and up to 14 days postpartum without another attributable cause and clinical or laboratory signs of preeclampsia.24,25

Data collection
We identified all the babies with adverse perinatal outcomes using the digitalized parturition books of every hospital maternity ward. The medical files were retrieved for all perinatal deaths to extract additional variables and for in-depth case review.

Within the Suriname Obstetrical Surveillance System, all women with (P)LTCs were identified according to the WHO near miss approach.22 Medical doctors from each facility prospectively screened the medical files of discharged patients in the delivery rooms, maternity wards, and the intensive care unit weekly. Data were extracted from the medical files and digitalized anonymously in Microsoft Excel (Microsoft Corporation, Redmond, WA) and SPSS (IBM, Chicago, IL). Retrieved data included demographic information, patient history, and maternal outcomes (eg, blood loss, mode of birth, and WHO near miss organ dysfunction).22 All maternal deaths were identified and reviewed by the expert committee Maternal Mortality Suriname.18

Data for the control group, all hospital births among women without severe morbidity or without adverse perinatal outcomes, were anonymously extracted from the digitalized parturition books of every hospital maternity ward. The data were cross-checked with the paper parturition books and missing or incorrect data were corrected using the paper medical file. The retrieved data did not include information on the use of antenatal corticosteroids, however, the administration of corticosteroids in expected premature birth (<34 weeks’ gestation) is a routine procedure in Suriname.

Statistical analysis
We used IBM SPSS version 24 (IBM Corp, Armonk, NY) for data analysis. Multiple pregnancies were excluded from the analyses. We conducted descriptive data analyses for frequencies (percentages), means (standard deviation), and medians (interquartile range [IQR]) if not normally distributed. Categorical variables were analyzed using cross-tabulations and chi-square tests for significance (P<.05). We performed univariate logistic regression analyses to assess maternal factors associated with adverse perinatal outcomes and reported outcomes in crude odds ratios (cORs) with 95% confidence intervals (95% CIs). Possible confounders were identified by constructing causal diagrams based on existing literature and were included in the multivariable logistic regression. We performed a multivariable logistic regression to consider confounders, reported as adjusted ORs (aORs) with 95% CIs. A similar analysis was conducted to assess perinatal outcomes among women with severe HDPs in comparison with women without severe HDPs.

Ethical approval
This research was reviewed and approved by the ethical review board of the Surinamese Committee on Research Involving Human Subjects (approval number VG21-16) on October 4, 2016. No additional approval was required for the analysis of anonymous data.

Results
Over the 1-year study period, there were 9197 hospital births and 9073 singletons born. There were 445 (4.8%) women with severe morbidity (ie, PTLC) of whom 59 (13.3%), 59/445 were considered MNMs (ie, LTC) (Figure). Of the 9073 singletons, 638 babies (7.0%) experienced an adverse perinatal outcome. Almost 1 in 5 babies born with an adverse perinatal outcome were born to women with severe morbidity (18.8%, n=120/638). Of these women, 79.2% (n=95/120) had severe HDPs. Table 1 reports the association between different types of maternal morbidities and adverse perinatal outcomes. Severe HDPs significantly increased the risk for an adverse perinatal outcome (aOR, 11.1; 95% CI, 8.3–14.9).

The prevalence of women with severe HDPs in Suriname was 2.5% (n=234/9197); severe preeclampsia occurred in 2.1% of the pregnancies (n=189/9197) and eclampsia in 0.5% (n=45/9197). Three of 10 maternal deaths were caused by severe HDPs. Table 2 presents the birth outcomes for women with a singleton pregnancy who experienced severe HDPs (n=215) vs those who did not experience severe HDPs. Women with severe HDPs gave birth to a baby with an adverse perinatal outcome in 44.2% of cases (n=95/215; aOR, 11.1; 95% CI, 8.3–14.9); 18.1% suffered a perinatal death (n=39/215; aOR, 8.6; 95% CI, 5.8–12.7) and 26.0% (n=56/215) experienced a neonatal near miss (Table 2). Stillbirth occurred in 13.5% of cases (n=29/215; aOR, 7.8; 95% CI, 5.0–12.2) and early neonatal deaths in 4.7% of cases (n=10/215). Women with severe HDPs gave birth to a preterm baby in 67.1% of the cases (n=143; aOR, 14.1; 95% CI, 10.5–19.0), a baby with low birthweight in 62.2% of cases (n=130; aOR, 10.8; 95% CI, 8.1–14.5), and a baby with a low 5-minute Apgar score in 20.5% of cases (n=43; aOR, 6.9; 95% CI, 4.8–10.0).

Comment
Principal findings
This nationwide study in Suriname shows a strong association between different maternal morbidities and adverse perinatal outcomes. One in 5 babies born with an adverse perinatal outcome are born to women with severe morbidities of whom the majority suffer from severe HDPs. Severe HDPs increased the risk for an adverse perinatal outcome by >10 times. In Suriname, 1 in 40 pregnant women experience severe HDPs. These women have an 18% risk
for perinatal death and 26% risk for neonatal near miss. Therefore, prevention, early detection, and improvement in the management of HDPs are crucial to improve perinatal health and are key to reducing perinatal mortality in LMICs such as Suriname.

**Results in context**

Previous studies in LMICs reported increased odds of having a low birthweight neonate (aOR, 2.8–8.0), preterm birth (aOR, 2.5–3.3), neonate with a low Apgar score (aOR, 2.7–2.9), and stillbirth (aOR, 3.3–6.3) among women with HDPs.6,7,26−28 (Supplemental Table 2). However, these odds are lower than reported in our study in Suriname. The prevalence of preeclampsia in Latin America and the Caribbean is 6.0%.6 However, very few studies reported the prevalence of severe HDPs in the region, nor its impact on perinatal outcomes.12 The heterogeneous definitions of severe HDPs hamper data comparisons (Supplemental Table 2).26,27,29 Nevertheless, even studies using a similar definition of severe HDPs report varying prevalences, from 8.1% (Brazil) to 0.8% (Tanzania), because effective monitoring leads to higher detection rates of severe HDPs.29,30

Studies on perinatal outcomes are crucial to reduce perinatal mortality and work toward the global goal of <12 perinatal deaths per 1000 births by 2030.1 The number of studies investigating perinatal health is rising rapidly.1,2,14 However, because no universal definition or outcome measure of a neonatal near miss is in place, a global data comparison is unfeasible and unachievable.31,32 A combined outcome measure for adverse perinatal outcomes and uniform neonatal near miss criteria are crucial for global data comparisons and are particularly useful for countries with a low number of perinatal deaths (high-income settings and countries with a small population and a low absolute number of perinatal deaths).

**Clinical implications**

Previous studies showed a strong relationship between MNM and adverse perinatal outcomes and identified the need to incorporate perinatal aspects into the MNM approach.3,33 Although women with MNM criteria may have the greatest risk for adverse perinatal outcomes, our study showed that most adverse perinatal outcomes occurred in women who did not meet the PLTC or LTC (MNM) criteria. However, these women might suffer from “milder diseases” such as gestational diabetes or mild preeclampsia. In summary, the MNM approach should indeed integrate adverse perinatal outcomes, but perinatal death and neonatal near miss reviews also need to incorporate all maternal factors to identify both mild
and severe maternal complications that impact perinatal health. Although understanding the rates and trends helps to identify opportunities to prevent and manage pregnancy complications that can lead to perinatal deaths, the next step is to go beyond the numbers and introduce perinatal death reviews among women with severe HDPs. The lessons learned and the recommendations established from systematic, critical analysis of the care received in a no-blame interdisciplinary setting provide an opportunity to implement new guidelines, improve perinatal health, and reduce adverse outcomes.34

**Research implications**

Improving perinatal health requires an approach that includes different aspects of maternal and perinatal care. Prevention and adequate management of HDPs are essential to reduce perinatal deaths and enhance perinatal outcomes. Local recommendations based on this study can be found in the Box. In addition, evidence-based interventions that may help to reduce HDP-related morbidity include (1) improved uptake of aspirin use among high-risk pregnant women, (2) improving access to care, particularly for high-risk women in the third trimester, and (3) optimizing blood pressure management during antenatal and postnatal care.35−37

Lastly, we call for a universal definition for an adverse perinatal outcome to harmonize and compare data across and within diverse settings.

**TABLE 1**

| Maternal factors associated with adverse perinatal outcomes |
|-------------------------------------------------------------|
| **Factors** | Total (n) |
| Births | 9197 |
| Total singleton babies born | 9073 |
| Singleton live births | 8885 |

| Maternal factors | No adverse perinatal outcome (n=8435) (%) | Adverse perinatal outcome (n=638) (%) | cOR (95% CI) | aOR (95% CI) |
|-----------------|-----------------------------------|-----------------------------------|--------------|-------------|
| Severe HDP (vs women without severe HDP) | 120 (1.4) | 95 (14.9) | 12.1 (9.1−16.2) | 11.1 (8.3−14.9) |
| ICU admission (vs women without ICU admission) | 57 (0.7) | 32 (5.0) | 7.8 (5.0−12.1) | 7.6 (4.9−12.0) |
| Severe sepsis (vs women without severe sepsis) | 19 (0.2) | 13 (2.0) | 9.2 (4.5−18.7) | 8.2 (3.7−17.9) |
| Severe PPH (vs women without severe PPH) | 152 (1.8) | 33 (5.2) | 3.0 (2.0−4.4) | 2.8 (1.9−4.1) |
| WHO MNM (vs women without WHO MNM) | 34 (0.4) | 23 (3.6) | 9.2 (5.4−15.8) | 8.8 (5.2−15.1) |
| Maternal death | 3 (0.0) | 6 (0.9) | — | — |

| Maternal morbidityc | No adverse perinatal outcome (n=8435) (%) | Adverse perinatal outcome (n=638) (%) | cOR (95% CI) | aOR (95% CI) |
|-----------------|-----------------------------------|-----------------------------------|--------------|-------------|
| <20 (vs ≥20) | 1134 (13.5) | 96 (15.1) | 1.1 (0.9−1.4) | — |
| >35 (vs ≤35) | 923 (11.0) | 85 (13.4) | 1.3 (0.9−1.6) | — |

| Ethnicity | No adverse perinatal outcome (n=8435) (%) | Adverse perinatal outcome (n=638) (%) | cOR (95% CI) | aOR (95% CI) |
|-----------------|-----------------------------------|-----------------------------------|--------------|-------------|
| African descent (vs other ethnicities) | 4169 (50.2) | 385 (62.8) | 1.7 (1.4−2.0) | 1.7 (1.5−2.0) |
| Asian descent (vs other ethnicities) | 2688 (32.4) | 141 (23.0) | 0.6 (0.5−0.8) | 0.6 (0.5−0.8) |

| Parity | No adverse perinatal outcome (n=8435) (%) | Adverse perinatal outcome (n=638) (%) | cOR (95% CI) | aOR (95% CI) |
|-----------------|-----------------------------------|-----------------------------------|--------------|-------------|
| Nulliparous (vs other) | 2886 (34.3) | 233 (36.9) | 1.1 (0.9−1.3) | — |
| Grande multiparous (vs other) | 1092 (13.0) | 107 (16.9) | 1.4 (1.1−1.7) | 1.2 (0.9−1.5) |

| Missing | 27 | 6 |

aOR, adjusted odds ratio; CI, confidence interval; cOR, crude odds ratio; HDP, hypertensive disorders of pregnancy; ICU, intensive care unit; MNM, maternal near miss; PPH, postpartum hemorrhage; WHO, World Health Organization.

3 Presence of 1 of the following: perinatal death, birthweight <1750 g, gestational age <33 weeks, 5-minute Apgar score <7, or a gestational age between 33 and 37 weeks with a birthweight percentile <p3. Multiple pregnancies excluded; 3 Adjusted for maternal age, ethnicity, and parity; 3 According to WHO Near Miss Tool. Other severe maternal morbidity included cardiac disease (n=7, of which 1 had an adverse perinatal outcome), thrombo-embolism (n=4 of which 1 had an adverse perinatal outcome), and diabetic keto-acidosis (n=1 with adverse perinatal outcome); 3 Significant at a P value <.001.

Prüst. Impact of severe hypertensive disorders of pregnancy on perinatal outcomes in Suriname. Am J Obstet Gynecol Glob Rep 2021.
| Perinatal outcomes                  | Women without severe HDPn (%) | Women with severe HDPn (%) | cOR (95% CI) | aOR (95% CI) | P value |
|------------------------------------|-------------------------------|-----------------------------|--------------|--------------|---------|
| **Total**                          | 8858                          | 215                         |              |              |         |
| **Adverse perinatal outcome** b    | 543 (6.1)                    | 95 (44.2)                   | 12.1 (9.1–16.1) | 11.1 (8.3–14.9) | <.001   |
| **Stillbirth**                     |                               |                             |              |              |         |
| Total                              | 159 (1.8)                    | 29 (13.5)                   | 8.5 (5.6–13.0) | 7.8 (5.0–12.2) | <.001   |
| <28 wk                             | 58 (36.5)                    | 9 (31.0)                    |              |              |         |
| 28–36 wk                           | 68 (42.8)                    | 19 (65.5)                   |              |              |         |
| ≥37 wk                             | 32 (20.1)                    | 1 (3.4)                     |              |              |         |
| **Early neonatal deaths** c        | 46 (0.5)                     | 10 (4.7)                    |              |              |         |
| **Perinatal deaths** d             | 205 (2.3)                    | 39 (18.1)                   | 9.4 (6.4–13.6) | 8.6 (5.8–12.7) | <.001   |
| **Gestational age at birth**       |                               |                             |              |              |         |
| Median (IQR)                       |                               |                             |              |              |         |
| <31 wk                             | 232 (2.6)                    | 49 (23.0)                   | 23.4 (15.8–34.5) | 22.5 (15.1–33.6) | <.001   |
| 32–36 wk                           | 848 (9.6)                    | 94 (44.1)                   | 12.3 (8.9–16.9) | 11.9 (8.6–16.4) | <.001   |
| ≥37 wk                             | 7753 (87.8)                  | 70 (32.9)                   | Reference group |              |         |
| **Birthweight**                    |                               |                             |              |              |         |
| Median (IQR)                       |                               |                             |              |              |         |
| <1000 g                            | 109 (1.2)                    | 20 (9.6)                    | 17.9 (10.6–30.2) | 18.4 (10.7–31.5) | <.001   |
| 1000–2499 g                        | 1013 (11.5)                  | 110 (52.6)                  | 10.6 (7.9–14.2) | 10.1 (7.4–13.6) | <.001   |
| ≥2500 g                            | 7692 (87.3)                  | 79 (37.8)                   | Reference group |              |         |
| **Apgar 1-min**                    |                               |                             |              |              |         |
| <7                                 | 427 (4.9)                    | 59 (27.8)                   | 7.5 (5.3–10.7) | 6.7 (4.9–9.3) | <.001   |
| ≥7                                 | 8347 (95.1)                  | 153 (72.2)                  | Reference group |              |         |
| **Apgar 5-min**                    |                               |                             |              |              |         |
| <7                                 | 291 (3.3)                    | 43 (20.5)                   | 7.5 (5.3–10.7) | 6.9 (4.8–10.0) | <.001   |
| ≥7                                 | 8487 (96.7)                  | 167 (79.5)                  | Reference group |              |         |
| **Mode of birth**                  |                               |                             |              |              |         |
| Vaginal birth                       | 6867 (77.5)                  | 80 (37.2)                   | Reference group |              |         |
| Cesarean delivery                  | 11,991 (22.5)                | 135 (62.8)                  | 5.8 (4.4–7.7) | 6.8 (5.1–9.2) | <.001   |
| **Missing**                        | 0                             | 0                           |              |              |         |

Data are presented as number (percentage), unless otherwise indicated.

HDP: hypertensive disorders of pregnancy; OR: odds ratio.

a Adjusted for maternal age, ethnicity, and parity; b Presence of 1 of the following: perinatal death, birthweight <1750 g, gestational age <33 weeks, 5-min Apgar <7, or a gestational age between 33 and 37 weeks with a birthweight percentile <p3. Multiple pregnancies excluded; c Death within 7 days after birth; d Sum of stillbirths (gestational age >22 weeks) and early neonatal death (<7 days after birth).

Prust. Impact of severe hypertensive disorders of pregnancy on perinatal outcomes in Suriname. Am J Obstet Gynecol Glob Rep 2021.
Strengths and limitations
The strength of the study lies in its nationwide design and the prospective data collection with all uncomplicated hospital births being used as a reference group. In addition, we applied international WHO definitions, easing global comparisons. One of our limitations is that risk factors such as body mass index and socioeconomic status were not available and could not be included in the multivariate regression analysis. Another limitation is that underreporting of neonatal deaths is possible, and we could have missed a death if a baby died at home without it being reported to the hospital.

Conclusions
Severe HDPs increase the risk for adverse perinatal outcomes by >10 times. One in 5 women with severe HDPs suffers a perinatal death. These findings emphasize that prevention, early diagnosis, and management of HDPs are key components in the reduction of adverse perinatal outcomes in Suriname. A global consensus is necessary to create a universal definition for adverse perinatal outcome and harmonize data comparisons. In addition, perinatal death and neonatal death near miss audits are necessary to assess factors contributing to the large proportion of poor perinatal outcomes in women without severe maternal morbidity.

ACKNOWLEDGMENTS
The authors would like to thank the Surinamese College of Gynecologists and Obstetricians, the confederation of midwives in Suriname, and the expert committee Maternal Mortality Suriname. We thank Raaz Paidin, MD (gynecology resident at Diakonessenhuis Paramaribo) and Rubinha Paidin, MD (gynecology resident at Academic Hospital Paramaribo), for their help with the data collection. Raaz Paidin and Rubinha Paidin were not financially compensated for their work on this study. We thank the medical directors and the registries of the 5 hospitals for their cooperation. We are grateful for the effort of the medical archive personnel of the 5 hospitals who made the paper and digital parturition book data available. We thank the medical students who voluntarily contributed to the data acquisition.

Supplementary materials
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jxagr.2021.100027.

REFERENCES
1. World Health Organization. Every Newborn: an action plan to end preventable deaths. Available at: http://www.healthynewbornnetwork.org/rrn-content/uploads/Every-Newborn_Action_Plan-ENGLISH_updated_July2014.pdf. Accessed April 7, 2021.
2. World Health Organization. Neonatal and perinatal mortality: country, regional and global estimates. Available at: https://apps.who.int/iris/handle/10665/43444. Accessed April 7, 2021.
3. Zarandi DM, Parpinelli MA, Haddad SM, et al. Adverse perinatal outcomes are associated with severe maternal morbidity and mortality: evidence from a national multicenter cross-sectional study. Arch Gynecol Obstet 2019;299:645–54.
4. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2001;25:120–7.
5. Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of pre-eclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol 2013;170:1–7.
6. Bilano VL, Ota E, Ganchimeg T, Mori R, Souza JP. Risk factors of pre-eclampsia/eclampsia and its adverse outcomes in low- and middle-income countries: a WHO secondary analysis. PLoS One 2014;9:91198.

7. McKenzie KA, Trotman H. A retrospective study of neonatal outcome in pre-eclampsia at the University Hospital of the West Indies: a resource-limited setting. J Trop Pediatr 2019;65:78–83.
8. World Health Organization. Prevention and treatment of pre-eclampsia and eclampsia. Available at: https://apps.who.int/iris/bitstream/handle/10665/44703/9789241548335_eng.pdf;jsessionid=1787520492F2A5296AC2E935D7?sequence=1. Accessed April 7, 2021.
9. Wallis AB, Saffias AF, Hsia J, Atrash HK. Secular trends in the rates of pre-eclampsia, eclampsia, and gestational hypertension, United States, 1987–2004. Am J Hypertens 2008;21:521–6.
10. The Pan American Health Organization. Noncommunicable disease risk factors in the Americas: considerations on the strengthening or regulatory capacity. Available at: https://iris.paho.org/bitstream/handle/10665.2/10024/9789275118665rev_eng.pdf?sequence=5&isAllowed=y. Accessed April 7, 2021.
11. Khan KS, Wojdyla D, Say L, Gürmeçoglu AM, van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet 2006;367:1066–74.
12. Phoa KY, Chedraui P, Pérez-López FR, et al. Perinatal outcome in singleton pregnancies complicated with preeclampsia and eclampsia in Ecuador. J Obstet Gynecol 2016;36:581–4.
13. Duley ZD, Verschueren KJC, Bhikha-Kori GAA, et al. Investigation of stillbirth causes in Suriname: application of the WHO ICD-PM tool to national-level hospital data. Glob Health Action 2020;13:1794105.
14. Verschueren KJC, Duley ZD, Paidin RR, et al. Childbirth outcomes and ethnic disparities in Suriname: a nationwide registry-based study in a middle-income country. Reprod Health 2020;17:62.
15. The World Bank. Population total—Suriname. Available at https://data.worldbank.org/indicator/SP.POP.TOTL?locations=SR. Accessed April 7, 2021.
16. Ministry of Social Affairs, Housing, General Bureau of Statistics. Monitoring the situation of children and women. Available at: https://datacatalog.worldbank.org/dataset/suriname-multipletindicator-cluster-survey-2018. Accessed April 7, 2021.
17. Verschueren KJC, Kodan LR, Brinkman TK, et al. Bottom-up development of national obstetric guidelines in middle-income country Suriname. BMC Health Serv Res 2019;19:651.
18. Kodan LR, Verschueren KJC, van Rosmalen J, Kanhai HHH, Bloemkamp KWM. Maternal mortality audit in Suriname between 2010 and 2014, a reproductive age mortality survey. BMC Pregnancy Childbirth 2017;17:275.
19. World Health Organization. The WHO application of ICD-10 to deaths during the perinatal period: ICD-PM. Available at: https://apps.who.int/iris/bitstream/handle/10665/
21. Pileggi-Castro C, Camelo JS, Perdoná GC, et al. Development of criteria for identifying neonatal near-miss cases: analysis of two WHO multicountry cross-sectional studies. BJOG 2014;121(Suppl1):110–8.

22. World Health Organization. Evaluating the quality of care for severe pregnancy complications: the WHO near-miss approach for maternal health. Available at: http://www.who.int/reproductivehealth/publications/monitoring/9789241502221/en/. Accessed April 7, 2021.

23. Verschueren KJC, Kodan LR, Paidin RR, et al. Applicability of the WHO maternal near-miss tool: a nationwide surveillance study in Suriname. J Glob Health 2020;10:020429.

24. Schaap T, Bloemenkamp K, Deneux-Tharaux C, et al. Defining definitions: a Delphi study to develop a core outcome set for conditions of severe maternal morbidity. BJOG 2019;126:394–401.

25. Verschueren KJC, Paidin RR, Broekhuis A, et al. Why magnesium sulphate ‘coverage’ only is not enough to reduce eclampsia: lessons learned in a middle-income country. Pregnancy Hypertens 2020;22:136–43.

26. Olusanya BO, Solanke OA. Perinatal outcomes associated with maternal hypertensive disorders of pregnancy in a developing country. Hypertens Pregnancy 2012;31:120–30.

27. Browne JL, Vissers KM, Antwi E, et al. Perinatal outcomes after hypertensive disorders in pregnancy in a low resource setting. Trop Med Int Health 2015;20:1778–86.

28. Bridwell M, Handzel E, Hynes M, et al. Hypertensive disorders in pregnancy and maternal and neonatal outcomes in Haiti: the importance of surveillance and data collection. BMC Pregnancy Childbirth 2019;19:208.

29. Mooij R, Lugumila J, Mwashambwa MV, Mwampagatwa NH, van Dillen J, Stekelenburg J. Characteristics and outcomes of patients with eclampsia and severe pre-eclampsia in a rural hospital in Western Tanzania: a retrospective medical record study. BMC Pregnancy Childbirth 2015;15:213.

30. Zanette E, Parpinelli MA, Surita FG, et al. Maternal near miss and death among women with severe hypertensive disorders: a Brazilian multicenter surveillance study. Reprod Health 2014;11:4.

31. Santos JP, Cercatti JG, Serruya SJ, et al. Neonatal near miss: the need for a standard definition and appropriate criteria and the rationale for a prospective surveillance system. Clinics (Sao Paulo) 2015;70:820–6.

32. Santos JP, Pileggi-Castro C, Camelo Jr JS, et al. Neonatal near miss: a systematic review. BMC Pregnancy Childbirth 2015;15:320.

33. Tura AK, Scheron J, van Roosmalen J, Zwart J, Stekelenburg van den Akker T. Surviving mothers and lost babies - burden of stillbirths and neonatal deaths among women with maternal near miss in eastern Ethiopia: a prospective cohort study. J Glob Health 2020;10:01041310.

34. World Health Organization. Making Every Baby Count: audit and review of stillbirths and neonatal deaths. Available at: https://www.who.int/docs/default-source/mca-documents/maternal-nb/making-every-baby-count.pdf?sfvrsn=6936f980_2. Accessed April 7, 2021.

35. Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet 2019;145(Suppl1):1–33.

36. Townsend R, O’Brien P, Khalil A. Current best practice in the management of hypertensive disorders in pregnancy. Integr Blood Press Control 2016;9:79–94.

37. Salam RA, Das JK, Ali A, Bhaumik S, Lassi ZS. Diagnosis and management of pre eclampsia in community settings in low and middle-income countries. J Family Med Prim Care 2015;4:501–6.